Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Reports Q4 revenue $4.56B, consensus $4.42B. “2024 was one of the best years in the history of Boston Scientific (BSX), fueled by our ...

The company said, “The company estimates net sales growth for the full year 2025, versus the prior year period, to be in a range of approximately 12.5 to 14.5 percent on a reported basis, and ...

For the current quarter ending in March, Boston Scientific expects its per-share earnings to range from 66 cents to 68 cents. The company expects full-year earnings in the range of $2.80 to $2.87 per ...

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.